Qian Guoqing, Zhang Yong, Xu Yang, Hu Weihua, Hall Ian P, Yue Jiang, Lu Hongyun, Ruan Liemin, Ye Maoqing, Mei Jin
Department of General Internal Medicine, Ningbo First Hospital, Zhejiang University, Ningbo, Zhejiang, China.
Division of Respiratory Medicine, National Institute for Health Research, Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, United Kingdom.
EClinicalMedicine. 2021 Apr;34:100831. doi: 10.1016/j.eclinm.2021.100831. Epub 2021 Apr 15.
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children is associated with better outcomes than in adults. The inflammatory response to COVID-19 infection in children remains poorly characterised.
We retrospectively analysed the medical records of 127 laboratory-confirmed COVID-19 patients aged 1 month to 16 years from Wuhan and Jingzhou of Hubei Province. Patients presented between January 25th and March 24th 2020. Information on clinical features, laboratory results, plasma cytokines/chemokines and lymphocyte subsets were analysed.
Children admitted to hospital with COVID-19 were more likely to be male (67.7%) and the median age was 7.3 [IQR 4.9] years. All but one patient with severe disease was aged under 2 and the majority (5/7) had significant co-morbidities. Despite 53% having viral pneumonia on computed tomography (CT) scanning only 2 patients had low lymphocyte counts and no differences were observed in the levels of plasma proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis factor (TNF)- , and interferon (IFN)- between patients with mild, moderate or severe disease.
We observed that the immune responses of children to COVID-19 infection is significantly different from that seen in adults. Our evidence suggests that SARS-CoV-2 does not trigger a robust inflammatory response or 'cytokine storm' in children with COVID-19, and this may underlie the generally better outcomes seen in children with this disease.
儿童感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的预后优于成人。儿童对2019冠状病毒病(COVID-19)感染的炎症反应仍未得到充分描述。
我们回顾性分析了湖北省武汉和荆州127例年龄在1个月至16岁之间实验室确诊的COVID-19患者的病历。患者于2020年1月25日至3月24日就诊。分析了临床特征、实验室检查结果、血浆细胞因子/趋化因子和淋巴细胞亚群的信息。
因COVID-19入院的儿童更可能为男性(67.7%),中位年龄为7.3岁[四分位间距4.9]。除1例重症患者外,所有重症患者年龄均在2岁以下,大多数(5/7)有明显的合并症。尽管53%的患者在计算机断层扫描(CT)上显示有病毒性肺炎,但只有2例患者淋巴细胞计数低,轻度、中度或重度疾病患者的血浆促炎细胞因子水平,包括白细胞介素(IL)-2、IL-4、IL-6、肿瘤坏死因子(TNF)-α和干扰素(IFN)-γ,均未观察到差异。
我们观察到儿童对COVID-19感染的免疫反应与成人显著不同。我们的证据表明,SARS-CoV-2不会在患有COVID-19的儿童中引发强烈的炎症反应或“细胞因子风暴”,这可能是该疾病儿童总体预后较好的原因。